The FDA approved toripalimab-tpzi (Loqtorz, Coherus BioSciences) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma. The FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic nasopharyngeal carcinoma with disease progression on or after a platinum-containing chemotherapy.
Efficacy of toripalimab-tpzi with cisplatin and gemcitabine was evaluated in
OCTOBER 30, 2023